Avalyn to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024 08:00 ET
|
Avalyn Pharma Inc.
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhalation therapies for life-threatening pulmonary...
Avalyn to Participate in Multiple Upcoming Investor Conferences
February 06, 2024 08:00 ET
|
Avalyn Pharma Inc.
CAMBRIDGE, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhalation therapies for life-threatening pulmonary...
Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference
December 06, 2023 08:00 ET
|
Avalyn Pharma Inc.
SEATTLE, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
November 09, 2023 08:00 ET
|
Avalyn Pharma Inc.
Preclinical data that supported initiation of the completed Phase 1a AP02 inhaled nintedanib study to be presented for the first time at the PFF Summit AP01 inhaled pirfenidone clinical data,...
Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
November 06, 2023 08:00 ET
|
Avalyn Pharma Inc.
SEATTLE, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
Avalyn to Participate in Multiple Upcoming Investor Conferences
October 05, 2023 08:00 ET
|
Avalyn Pharma Inc.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference
September 29, 2023 06:30 ET
|
Avalyn Pharma Inc.
SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
September 27, 2023 06:30 ET
|
Avalyn Pharma Inc.
Financing led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, with participation by new and current healthcare investors Funds to support Phase 2b development of AP01...
Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit
September 18, 2023 12:06 ET
|
Avalyn Pharma Inc.
Seattle, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
September 12, 2023 08:00 ET
|
Avalyn Pharma Inc.
Seattle, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, and...